203 related articles for article (PubMed ID: 16932460)
1. Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
Kiberd BA
Nat Clin Pract Nephrol; 2006 Jul; 2(7):354-5. PubMed ID: 16932460
[No Abstract] [Full Text] [Related]
2. A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease.
Takagi H; Umemoto T
Int J Cardiol; 2011 Oct; 152(2):242-4. PubMed ID: 21764159
[No Abstract] [Full Text] [Related]
3. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641
[No Abstract] [Full Text] [Related]
4. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
[TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
[TBL] [Abstract][Full Text] [Related]
6. Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?
Kwan BC; Beddhu S; Kronenberg F; Cheung AK
Nat Clin Pract Nephrol; 2006 Feb; 2(2):76-7. PubMed ID: 16932397
[No Abstract] [Full Text] [Related]
7. DUAAL: atorvastatin provided an unexpectedly potent heart benefit in patients with chronic stable angina.
Cardiovasc J Afr; 2008; 19(3):174. PubMed ID: 18568187
[No Abstract] [Full Text] [Related]
8. Atorvastatin and amlodipine: the successful duet that led to Caduet.
Cardiovasc J Afr; 2009; 20(1):87-8. PubMed ID: 19287825
[No Abstract] [Full Text] [Related]
9. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Bianchi S; Bigazzi R; Caiazza A; Campese VM
Am J Kidney Dis; 2003 Mar; 41(3):565-70. PubMed ID: 12612979
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin (Lipitor).
Tucker G
Conn Med; 1998 May; 62(5):283-5. PubMed ID: 9639958
[No Abstract] [Full Text] [Related]
11. Benefits of atorvastatin in cholesterol lowering.
Farmer JA
Curr Atheroscler Rep; 2003 Mar; 5(2):94-5. PubMed ID: 12573192
[No Abstract] [Full Text] [Related]
12. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
Bern VH
Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
[No Abstract] [Full Text] [Related]
13. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
Lafuma A; Colin X; Solesse A
Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
16. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.
Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ;
J Hypertens; 2011 Mar; 29(3):592-9. PubMed ID: 21297502
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
18. [Considerable LDL lowering is advantageous].
MMW Fortschr Med; 2005 Sep; 147(35-36):9. PubMed ID: 16180563
[No Abstract] [Full Text] [Related]
19. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
20. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
Frishman WH; Zuckerman AL
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):675-81. PubMed ID: 15350169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
